When citing an abstract from the 2023 annual meeting, please use the format below.

[Authors]. [Abstract Title]. Program No. XXX.XX. 2023 Neuroscience Meeting Planner. Washington, D.C.: Society for Neuroscience, 2023. Online.

Basic-Translational-Clinical Roundtables

BTCR01. Targeting Axon Degeneration in Peripheral Neuropathies — Ahmet Hoke

Location: WCC 206

Time: Sunday, November 12, 2023, 10:30 AM - 12:00 PM

Description: Distal axon degeneration is a principal cellular event resulting in symptoms in peripheral neuropathies. In this roundtable, advances in our understanding of the molecular mechanisms of programmed axon degeneration and its relevance to slow distal axon degeneration seen in peripheral neuropathies will be discussed and therapeutic targets and biomarkers will be highlighted.

Chair: A. Hoke;
Neurology, Johns Hopkins University, Baltimore, MD.

Disclosures: A. Hoke: E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); AxoProtego Therapeutics.

Speaker: A. Hoke;
Neurology, Johns Hopkins University, Baltimore, MD.

Disclosures: A. Hoke: E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); AxoProtego Therapeutics.

Speaker: M. P. Coleman;
University of Cambridge, Cambridge, UNITED KINGDOM.

Disclosures: M.P. Coleman: F. Consulting Fees (e.g., advisory boards); Nura Bio.

Speaker: S. Sambashivan;
Nura Bio, South San Francisco, CA.

Disclosures: S. Sambashivan: A. Employment/Salary (full or part-time):; NuraBio.

Basic-Translational-Clinical Roundtables

BTCR02. The Long Haul: Brain Dysfunction After Acute Illness — Joanna L. Spencer-Segal

Location: WCC 206

Time: Monday, November 13, 2023, 10:30 AM - 12:00 PM

Description: Patients who survive an acute illness frequently acquire new brain dysfunction, manifested as cognitive and affective symptoms. Long-term brain dysfunction can occur after systemic bacterial and viral infection treated both in and out of the intensive care unit. This session will describe the emerging understanding of the mechanisms that set the stage for

persistent brain dysfunction in survivors of acute illness, including the interaction of acute and pre-existing chronic pathology.

Chair: J. L. Spencer-Segal;
University of Michigan, Ann Arbor, MI.

Disclosures: J.L. Spencer-Segal: None.

Speaker: E. Wilcox;
University of Alberta, Alberta, AB, CANADA.

Disclosures: E. Wilcox: None.

Speaker: J. A. Hippensteel;
University of Colorado Anschutz Medical Campus, Aurora, CO.

Disclosures: J.A. Hippensteel: None.

Speaker: B. H. Singer;
University of Michigan, Ann Arbor, MI.

Disclosures: B.H. Singer: None.

Basic-Translational-Clinical Roundtables

BTCR03. Found in Translation: Medication Development for Substance Use Disorders From Animals to Humans — Jana Drgonova

Location: WCC Ballroom B

Time: Wednesday, November 15, 2023, 10:30 AM - 12:00 PM

Description: The roundtable aims to bring together scientists who move freely between discovery of targets for treatment of substance use disorders, preclinical medications development, and clinical trials. Speakers will share: experiences with moving discoveries through the translational pipeline to find new or repurposed pharmacotherapies; challenges overcome; and lessons learned.

Chair: J. Drgonova;
NIH, National Institute on Drug Abuse (NIDA), Rockville, MD.

Disclosures: J. Drgonova: None.

Speaker: N. C. Anastasio;
Center for Addiction Research, Univ Texas Med Branch, Galveston, TX.

Disclosures: N.C. Anastasio: None.

Speaker: P. S. Grigson;
Neural & Behavioral Sciences, PENNSYLVANIA STATE UNIV HERSHEY MED CTR, Hershey, PA.

Disclosures: P.S. Grigson: A. Employment/Salary (full or part-time):; Pennsylvania State University College of Medicine. B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; NIH/NIDA. C. Other Research Support (receipt of drugs, supplies, equipment or other in-kind support); Novo Nordisk/Donated liraglutide study drug.

Speaker: C. P. France;
University of Texas Health Science Center, San Antonio, TX.

Disclosures: C.P. France: A. Employment/Salary (full or part-time):; University of Texas Health Science Center at San Antonio. B. Contracted Research/Research Grant (principal investigator for a drug study, collaborator or consultant and pending and current grants). If you are a PI for a drug study, report that research relationship even if those funds come to an institution.; Principal Investigator: R01DA048417 and UH3DA048387C.. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Co-holder of US patent for methocinnamox.

Dual Perspectives

DUP01: Alzheimer's Targeted Treatments: Focus On Amyloid and Inflammation — Takeshi Iwatsubo

Location: WCC Ballroom A

Time: Sunday, November 12, 2023, 1:30 PM - 3:00 PM

Description: Progress in Alzheimer's disease (AD) research is enabling the development of disease-modifying therapies that slow down neurodegeneration-induced dementia. In this session, a moderator from academia, a spokesperson from Alzheimer's Association, and speakers from the pharmaceutical industry will present their perspectives on molecular targeted therapies. The contribution of neuroscience to AD therapies through the translation from bench to bedside will be discussed in the context of all stakeholders.

Moderator:
***T. IWATSUBO**;
Univ. of Tokyo, Tokyo, Japan

Disclosure: T. Iwatsubo: D. Fees for Non-CME Services Received Directly from Commercial Interest or their Agents (e.g., speakers' bureaus); speaker's compensation from Eisai.

Speakers: J. W. Lewcock;
Denali Therapeutics, South San Francisco, CA.

Disclosure: J.W. Lewcock: A. Employment/Salary (full or part-time); Denali Therapeutics. E. Ownership Interest (stock, stock options, royalty, receipt of intellectual property rights/patent holder, excluding diversified mutual funds); Denali Therapeutics.

Speakers: M. C. Carrillo;
Medical & Scientific Relations, Alzheimers Association, Chicago, IL.

Disclosure: M.C. Carrillo: None.

Speakers: M. C. Irizarry;
Eisai, Inc, Nutley, NJ.

Disclosure: M.C. Irizarry: A. Employment/Salary (full or part-time); Eisai, Inc.

Storytelling

STR01. Cross Cultural Narratives: On Being the Under-Resourced Neuroscientist — Jean A. King

Location: WCC Ballroom B

Time: Monday, November 13, 2023, 1:30 PM - 3:00 PM

Description: This storytelling session will highlight the experiences of four female neuroscientists discussing the cultural influences, stressors, challenges, and successes that shape their careers. The session is committed to bring to light the voices of people from other parts of the world, help expand a non-western viewpoints, and promote diversity and equity in science. All stories count.

STR01.01. Chair

Speaker: J. A. King;
Worcester Polytechnic Institute, Worcester Polytechnic Institute, Worcester, MA.

Disclosures: J.A. King: None.

STR01.02. Introduction

Speaker: *J. KING;
Worcester Polytechnic Inst., Worcester, MA

STR01.03. Psychophysiology of Stress: Pioneering work of psychophysiology and stress research in Pakistan

Speaker: S. AHMED;
UNIVERSITY OF KARACHI, KARACHI, PAKISTAN.

Disclosures: S. Ahmed: None.

SR01.04. Isolation, Stress and Mental Health: Animal and Human Studies in Puerto Rico

Speaker: A. C. Segarra;
University of Puerto Rico Medical Sciences Campus, San Juan, PR.

Disclosures: A.C. Segarra: None.

STR01.05. Early Life Stress, Behavior, Sexual Violence

Speaker: T. W. Shabangu;
University of Stellenbosch, Bellville, SOUTH AFRICA.

Disclosures: T.W. Shabangu: None.

STR01.06. Research on Brain Mechanisms, Psychotic Symptoms and Cognitive Deficits in Schizophrenia

Speaker: S. Bansal;
University of Maryland School of Medicine, Baltimore, MD.

Disclosures: S. Bansal: None.

STR01.07. Closing Remarks

Speaker: *J. KING;
Worcester Polytechnic Inst., Worcester, MA

STR02. Natives in Neuro: Building a Community of Indigenous Neuroscientists — McLester-Davis

Location: WCC Ballroom C

Time: Tuesday, November 14, 2023, 1:30 PM - 3:00 PM

Description: Indigenous people have contributed to science for thousands of years. From traditional ecological knowledge to the work of astronaut John Herrington and statistician Ross Ihaka, Natives in STEM have been integral to scientific progress. However, within neuroscience there are seldom spaces where Indigenous trainees can network. Sharing the stories of 5 Indigenous neuroscientists, we will chronicle the launch of NativesInNeuro and lay out a roadmap to giving back to Indigenous communities.

STR02.01. Chair

Speaker: L. W. McLester-Davis;
University of Wisconsin, Madison, WI.

Disclosures: L.W. McLester-Davis: None.

STR02.02. Introduction

Speaker: *L. W. MCLESTER-DAVIS;
Tulane Univ., New Orleans, LA

STR02.03. From Ivory Towers to Biopharma's Power: Navigating the ups and downs of career transition

Speaker: L. M. Cheadle;
Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.

Disclosures: L.M. Cheadle: None.

STR02.04. Preserving Our Traditions: Helping Our Elders Remember The Past

Speaker: M. Murie-Mazariegos;
Health Science, Nebraska Indian Community College, Macy, NE.

Disclosures: M. Murie-Mazariegos: None.

STR02.05. 0's and 1's: Organizing DEI Efforts As The Only Native in Your Department

Speaker: D. J. Acri;
Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, IN.

Disclosures: D.J. Acri: None.

STR02.06. Prioritizing Indigenous Communities' Priorities in Neuroscience Research

Speaker: L. W. McLester-Davis;
Tulane University, Tulane University, New Orleans, LA.

Disclosures: L.W. McLester-Davis: None.

STR02.07. Closing Remarks

Speaker: *L. W. MCLESTER-DAVIS;
Tulane Univ., New Orleans, LA